ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0269

Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease

Yiling Zhang1, Sara Tedeschi2, Abhishek Abhishek3, Owen Hensey4, David Grossberg5, Ken Cai6, Beverley Shea7, Jasvinder Singh8, Robin Christensen9, Teodora Serban10, Edoardo Cipolletta11, Konstantinos Parperis12, César Díaz13, Geraldine McCarthy14, Fabio Becce15, Tamer A Gheita16, Silvia Sirotti17, Sara Nysom Christiansen18, Luis Coronel Tarancon19, Lisa Stamp20, Yousra H Abdel-Fattah21, Tristan Pascart22, Georgios Filippou17, Lih En Hong23, John FitzGerald24 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Brigham and Women's Hospital, Boston, MA, 3University of Nottingham, Nottingham, United Kingdom, 4OMERACT patient research partner, Dublin, Ireland, 5OMERACT patient research partner, Maryland, 6Westmead Hospital, Sydney, New South Wales, Australia, 7Ottawa Hospital Research Institute, Ottawa, ON, Canada, 8Baylor College of Medicine, Birmingham, AL, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Ospedale La Colletta, Bucharest, Romania, 11Polytechnic University of Marche, Ancona, Italy, 12University of Cyprus Medical School, Nicosia, Cyprus, 13Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 14Mater Misericordiae University Hospital, Dublin, Ireland, 15Lausanne University Hospital (CHUV), Lausanne, Switzerland, 16Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 17IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, 18Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, 19Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, 20University of Otago, Christchurch, Christchurch, New Zealand, 21Alexandria University, Alexandria, Egypt, 22Lille Catholic University, Lille, France, 23Royal Adelaide Hospital, Unley Park, South Australia, Australia, 24UCLA, Los Angeles, CA

Meeting: ACR Convergence 2024

Keywords: , , ,

Session Information

Date: Saturday, November 16, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.

Methods: Patient research partners and other participants contributed to three rounds of a consensus survey using Delphi methodology. Consensus was defined if ≥70% of both patients and ‘other participant’ groups scored the domain as ‘critically important domain to include’. In a subsequent ranking exercise, all participants were asked to select and rank up to 10 of the domains reaching consensus as ‘critically important’.

Results: Fifteen domains reached consensus as critical. Within the Pathological Manifestations area, these were joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare, joint damage on imaging tests, joint calcification on imaging tests, and crystals in joint fluid. Within the Life Impact area, these were overall function, ability to complete daily tasks, ability to work, health related quality of life, patient global assessment response to treatment, patient global assessment of disease activity, physician global assessment of disease activity, and patient satisfaction with treatment. No domains within the Societal/Resource Use area reached consensus as critical. In the ranking exercise, joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare and overall function were most highly ranked.

Conclusion: This work has identified potential domains for inclusion into the OMERACT core domain set for long-term studies of CPPD disease. There was strong support for joint pain, joint tenderness, joint swelling, acute CPP crystal arthritis flare and overall function as critical domains.

Disclosures: Y. Zhang: None; S. Tedeschi: Alexion, 2, Avalo Therapeutics, 2, Merck, 2, Novartis, 2; A. Abhishek: Cadilla Pharmaceuticals, 9, Limbic consulting, 9, SOBI, 6, Uptodate, 9; O. Hensey: None; D. Grossberg: None; K. Cai: None; B. Shea: None; J. Singh: Adaptimmune Therapeutics, 2, Adept Field Solutions, 2, Aebona Pharmaceuticals, 11, Amarin, Viking and Moderna pharmaceuticals, 11, Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Ad, 11, Charlotte's Web Holdings, 11, Clinical Care options, 2, Enzolytics Inc, 11, Fidia, 2, Focus forward, 2, GeoVax Labs, 11, Intuitive Surgical Inc./Philips Electronics North America, 12, food and beverage payments, Jupiter Life Science, 2, MedIQ, 2, Medscape, 2, Medusas, 2, Navigant consulting, 2, Pieris Pharmaceuticals, 11, PK Med, 2, Practice Point communications, 2, Putnam associates, 2, ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals/DINORA, Frictionless Solution, 2, Schipher, 2, Seres Therapeutics, 11, speaker’s bureau of Simply Speaking, 6, Tonix Parmaceuticals, 11, Trio Health, 2, Two Labs Inc, 2, UBM LLC, 2, WebMD, 2, Zimmer Biomet Holdings, 5; R. Christensen: None; T. Serban: None; E. Cipolletta: Horizon Therapeutics, 2, IBSA, 6, Novartis, 6; K. Parperis: None; C. Díaz: None; G. McCarthy: Janssen, 12, Support for attending meetings, PKMed, 2; F. Becce: Horizon Therapeutics, 2, Siemens Healthineers, 5; T. A Gheita: None; S. Sirotti: None; S. Christiansen: Novartis, 5; L. Tarancon: None; L. Stamp: Uptodate, 9; Y. Abdel-Fattah: None; T. Pascart: None; G. Filippou: None; L. Hong: None; J. FitzGerald: Arthritis Foundation, 5, NIAMS, 5, NIDDK, 5; N. Dalbeth: Arthrosi, 2, AstraZeneca, 5, 6, Avalo Therapeutics, 2, Dexcel Pharma, 2, Hikma, 6, Horizon, 2, 6, JPI, 2, JW Pharmaceutical Corporation, 2, LG Chem, 2, Novartis, 6, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Shanton Pharma, 2, Sobi, 2, Unlocked Labs, 2.

To cite this abstract in AMA style:

Zhang Y, Tedeschi S, Abhishek A, Hensey O, Grossberg D, Cai K, Shea B, Singh J, Christensen R, Serban T, Cipolletta E, Parperis K, Díaz C, McCarthy G, Becce F, A Gheita T, Sirotti S, Christiansen S, Tarancon L, Stamp L, Abdel-Fattah Y, Pascart T, Filippou G, Hong L, FitzGerald J, Dalbeth N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/delphi-survey-to-establish-consensus-on-the-omeract-core-domain-set-for-long-term-studies-of-calcium-pyrophosphate-deposition-disease/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/delphi-survey-to-establish-consensus-on-the-omeract-core-domain-set-for-long-term-studies-of-calcium-pyrophosphate-deposition-disease/